JW (Cayman) Therapeutics Co (HKSE:02126) GF Value : HK$0.00 (As of Dec. 14, 2024)

View and export this data going back to 2020. Start your Free Trial

What is JW (Cayman) Therapeutics Co GF Value?

As of today (2024-12-14), JW (Cayman) Therapeutics Co's share price is HK$1.33. JW (Cayman) Therapeutics Co's GF Value is HK$0.00. Therefore, JW (Cayman) Therapeutics Co's Price-to-GF-Value for today is . Based on the relationship between the current stock price and the GF Value, GuruFocus believes JW (Cayman) Therapeutics Co is Not Valued.

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

JW (Cayman) Therapeutics Co (HKSE:02126) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

JW (Cayman) Therapeutics Co's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	1.33	/	0.00
	=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

JW (Cayman) Therapeutics Co GF Value Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

JW (Cayman) Therapeutics Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

JWCTF:USA JNY:Germany

Address

No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN

Website

https://www.jwtherapeutics.com

JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.

Executives

Li Dan	2202 Interest of your spouse
Li Yiping James	2201 Interest of corporation controlled by you
Syracuse Biopharma (cayman) Ii, Ltd.	2501 Other
Bristol-myers Squibb Company	2201 Interest of corporation controlled by you
Celgene Corporation	2201 Interest of corporation controlled by you
Juno Therapeutics, Inc.	2101 Beneficial owner
Syracuse Biopharma (cayman) Ltd.	2501 Other

JW (Cayman) Therapeutics Co Headlines

No Headlines